These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38556114)

  • 1. Development of a back-titration assay to quantitate functional lympho-epithelial Kazal-type inhibitors (LEKTI) in skin samples.
    Martins D; Pinoteau MA; Leger R
    Anal Biochem; 2024 Jul; 690():115524. PubMed ID: 38556114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toll-like receptor signaling induces the expression of lympho-epithelial Kazal-type inhibitor in epidermal keratinocytes.
    Sugimoto S; Morizane S; Nomura H; Kobashi M; Sugihara S; Iwatsuki K
    J Dermatol Sci; 2018 Nov; 92(2):181-187. PubMed ID: 30270115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor.
    Meyer-Hoffert U; Wu Z; Schröder JM
    PLoS One; 2009; 4(2):e4372. PubMed ID: 19190773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteolytic activation cascade of the Netherton syndrome-defective protein, LEKTI, in the epidermis: implications for skin homeostasis.
    Fortugno P; Bresciani A; Paolini C; Pazzagli C; El Hachem M; D'Alessio M; Zambruno G
    J Invest Dermatol; 2011 Nov; 131(11):2223-32. PubMed ID: 21697885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The identification of a new role for LEKTI in the skin: The use of protein 'bait' arrays to detect defective trafficking of dermcidin in the skin of patients with Netherton syndrome.
    Bennett K; Heywood W; Di WL; Harper J; Clayman GL; Jayakumar A; Callard R; Mills K
    J Proteomics; 2012 Jul; 75(13):3925-37. PubMed ID: 22588119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI).
    Schechter NM; Choi EJ; Wang ZM; Hanakawa Y; Stanley JR; Kang Y; Clayman GL; Jayakumar A
    Biol Chem; 2005 Nov; 386(11):1173-84. PubMed ID: 16307483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNF-α and IL-17A induce the expression of lympho-epithelial Kazal-type inhibitor in epidermal keratinocytes.
    Sugihara S; Sugimoto S; Tachibana K; Kobashi M; Nomura H; Miyake T; Hirai Y; Yamasaki O; Morizane S
    J Dermatol Sci; 2019 Oct; 96(1):26-32. PubMed ID: 31501002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPINK5 and Netherton syndrome: novel mutations, demonstration of missing LEKTI, and differential expression of transglutaminases.
    Raghunath M; Tontsidou L; Oji V; Aufenvenne K; Schürmeyer-Horst F; Jayakumar A; Ständer H; Smolle J; Clayman GL; Traupe H
    J Invest Dermatol; 2004 Sep; 123(3):474-83. PubMed ID: 15304086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LEKTI domains D6, D7 and D8+9 serve as substrates for transglutaminase 1: implications for targeted therapy of Netherton syndrome.
    Wiegmann H; Valentin F; Tarinski T; Liebau E; Loser K; Traupe H; Oji V
    Br J Dermatol; 2019 Nov; 181(5):999-1008. PubMed ID: 30801672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New role for LEKTI in skin barrier formation: label-free quantitative proteomic identification of caspase 14 as a novel target for the protease inhibitor LEKTI.
    Bennett K; Callard R; Heywood W; Harper J; Jayakumar A; Clayman GL; Di WL; Mills K
    J Proteome Res; 2010 Aug; 9(8):4289-94. PubMed ID: 20533828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LEKTI domain 15 is a functional Kazal-type proteinase inhibitor.
    Vitzithum K; Lauber T; Kreutzmann P; Schulz A; Sommerhoff CP; Rösch P; Marx UC
    Protein Expr Purif; 2008 Jan; 57(1):45-56. PubMed ID: 17936012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exonic mutations associated with atopic dermatitis disrupt lympho-epithelial Kazal-type related inhibitor action and enhance its degradation.
    Ramesh K; Matta SA; Chew FT; Mok YK
    Allergy; 2020 Feb; 75(2):403-411. PubMed ID: 31407378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LEKTI is localized in lamellar granules, separated from KLK5 and KLK7, and is secreted in the extracellular spaces of the superficial stratum granulosum.
    Ishida-Yamamoto A; Deraison C; Bonnart C; Bitoun E; Robinson R; O'Brien TJ; Wakamatsu K; Ohtsubo S; Takahashi H; Hashimoto Y; Dopping-Hepenstal PJ; McGrath JA; Iizuka H; Richard G; Hovnanian A
    J Invest Dermatol; 2005 Feb; 124(2):360-6. PubMed ID: 15675955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LEKTI-1 in sickness and in health.
    Roelandt T; Thys B; Heughebaert C; De Vroede A; De Paepe K; Roseeuw D; Rombaut B; Hachem JP
    Int J Cosmet Sci; 2009 Aug; 31(4):247-54. PubMed ID: 19467033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homologous Lympho-Epithelial Kazal-type Inhibitor Domains Delay Blood Coagulation by Inhibiting Factor X and XI with Differential Specificity.
    Ramesh K; Lama D; Tan KW; Nguyen VS; Chew FT; Verma CS; Mok YK
    Structure; 2018 Sep; 26(9):1178-1186.e3. PubMed ID: 30017565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. rAAV2-mediated restoration of LEKTI in LEKTI-deficient cells from Netherton patients.
    Roedl D; Oji V; Buters JT; Behrendt H; Braun-Falco M
    J Dermatol Sci; 2011 Mar; 61(3):194-8. PubMed ID: 21251800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant production, purification and biochemical characterization of domain 6 of LEKTI: a temporary Kazal-type-related serine proteinase inhibitor.
    Kreutzmann P; Schulz A; Ständker L; Forssmann WG; Mägert HJ
    J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Apr; 803(1):75-81. PubMed ID: 15026000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LEKTI: a multidomain serine proteinase inhibitor with pathophysiological relevance.
    Mägert HJ; Kreutzmann P; Ständker L; Walden M; Drögemüller K; Forssmann WG
    Int J Biochem Cell Biol; 2002 Jun; 34(6):573-6. PubMed ID: 11943586
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Park NJ; Jo BG; Bong SK; Park SA; Lee S; Kim YK; Yang MH; Kim SN
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kallikrein 5 Inhibition by the Lympho-Epithelial Kazal-Type Related Inhibitor Hinders Matriptase-Dependent Carcinogenesis.
    da Silva EZM; Fraga-Silva TFC; Yuan Y; Alves MG; Publio GA; da Fonseca CK; Kodama MH; Vieira GV; Candido MF; Innocentini LMAR; Miranda MG; da Silva AR; Alves-Filho JC; Bonato VLD; Iglesias-Bartolome R; Sales KU
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.